Le sugemalimab devient le premier anticorps monoclonal anti-PD-L1 approuvé en Europe pour le traitement de première intention du cancer du poumon non à petites cellules (CPNPC) squameux et non squameux. Il s’agit également de la première approbation internationale d’un anticorps…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.